Shalini Sharp currently serves on the Boards of Directors of Neurocrine Biosciences, Organon & Co and BeiGene. Previously, Ms. Sharp served as Chief Financial Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases, and Chief Financial Officer at Agenus, a clinical-stage immune-oncology company. Earlier, Ms. Sharp held positions at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs. Ms. Sharp previously served on the boards of Mirati Therapeutics (acquired by Bristol Myers Squibb), Sutro Biopharma, Precision Biosciences, and Agenus.
Ms. Sharp received her AB from Harvard College and her MBA from Harvard Business School.